Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2--Stained Clinical Specimens in Breast Cancer.

* Context.--Precise determination of biomarker status is necessary for clinical trial enrollment and endpoint analyses, as well as for optimal treatment determination in real-world practice. However, variabilities may be introduced into this process due to the processing of clinical specimens by dif...

Descripción completa

Detalles Bibliográficos
Publicado en:Archives of Pathology & Laboratory Medicine Vol. 149; no. 8; pp. 751 - 761
Autores principales: Glass, Benjamin, Vandenberghe, Michel E., Chavali, Surya Teja, Javed, Syed Ashar, Resnick, Murray, Pokkalla, Harsha, Elliott, Hunter, Rao, Sudha, Sridharan, Shamira, Brosnan-Cashman, Jacqueline A., Wapinski, Ilan, Montalto, Michael, Beck, Andrew H., Barker, Craig
Formato: pictorial research tables/charts Journal Article
Publicado: College of American Pathologists Aug2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187111457&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 187111457
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00039985
        1FS
      jtl: Archives of Pathology & Laboratory Medicine
      issn: 00039985
      maglogo: N
    pubinfo:
      dt: Aug2025
      vid: 149
      iid: 8
      pid: 2550
      pub: College of American Pathologists
      place: Northfield, Illinois
    artinfo:
      ui:
        187111457
        187111457
        187111457
        10.5858/arpa.2024-0111-OA
        187111457
      ppf: 751
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2--Stained Clinical Specimens in Breast Cancer.
      aug:
        au:
          Glass, Benjamin
          Vandenberghe, Michel E.
          Chavali, Surya Teja
          Javed, Syed Ashar
          Resnick, Murray
          Pokkalla, Harsha
          Elliott, Hunter
          Rao, Sudha
          Sridharan, Shamira
          Brosnan-Cashman, Jacqueline A.
          Wapinski, Ilan
          Montalto, Michael
          Beck, Andrew H.
          Barker, Craig
        affil: PathAI, Boston, Massachusetts
      sug:
        subj:
          Machine Learning
          Algorithms
          Quality Assessment
          Tumor Markers, Biological
          Epidermal Growth Factors Analysis
          Staining and Labeling
          Specimen Handling
          Breast Neoplasms Pathology
          Human
          Gene Expression
          HER-2-neu Oncogene
          Immunohistochemistry
          Artifacts
          Carcinoma, Ductal
          Image Processing, Computer Assisted
          Clinical Laboratories
          Descriptive Statistics
      ab: * Context.--Precise determination of biomarker status is necessary for clinical trial enrollment and endpoint analyses, as well as for optimal treatment determination in real-world practice. However, variabilities may be introduced into this process due to the processing of clinical specimens by different laboratories and assessment by distinct pathologists. Machine learning tools have the potential to minimize inconsistencies, although their use is not presently widespread. Objective.--To assess the applicability of machine learning to the quality control process for biomarker scoring in oncology, we developed and validated an automated machine learning model to be applied as a quality control tool for monitoring the assessment of human epidermal growth factor-2 (HER2). Design.--The model was trained using whole slide images from multiple sources to quantify HER2 expression and measure immunohistochemistry stain intensity, tumor area, and the presence of artifacts or ductal carcinoma in situ across breast cancer phenotypes. The quality control tool was deployed in a real-world cohort of HER2-stained breast cancer sample images collected from routine diagnostic practice to evaluate trends in HER2 testing quality indicators and between pathology laboratories. Results.--Automated image analysis for HER2 scoring is consistent and reliable using this algorithm. Deployment of the HER2 quality control tool across 3 clinical laboratories revealed interlaboratory variability in HER2 scoring and inconsistencies in data reporting. Conclusions.--These results support the future incorporation of quality control algorithms for real-time monitoring of clinical laboratories contributing to clinical trials in oncology and in the real-world setting of HER2 immunohistochemistry testing in local clinical laboratories and hospitals.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N